Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Shiseido: Domestic Sales Down for Both Cosmetics, Toiletries
May 27, 2002
- Pharmacies Employ Largest Number of Pharma Graduates
May 27, 2002
- Household Healthcare Costs Up 3.2%
May 27, 2002
- BMS: 1st Qtr Sales Down 7.0% to US$4.3 Bil.
May 27, 2002
- 12-hour Night Shift Work for Nurses Increasing: JNA Survey
May 27, 2002
- Eiken: Sales Up 2.5% to \21.3 Bil., Net Profits Up 44.4% to \1.2 Bil.
May 27, 2002
- JHSF Urges Makers to Beef Up Int'l Competitiveness in Genomic Drug Discovery
May 20, 2002
- WORLD NEWS IN BRIEF
May 20, 2002
- Trends in Informatics Reported by JHSF
May 20, 2002
- R&D Synergy to Accelerate Antibody Therapeutics: Chugai, Roche
May 20, 2002
- Increases in CAM-Resistant Hp Require Alternative Regimens
May 20, 2002
- Kumakura to Follow Path of His Predecessor: Kuraya Sanseido
May 20, 2002
- Epidural PCA Effective for Postoperative Pain
May 20, 2002
- JPMA Committee to Promote Patient-friendly Healthcare
May 20, 2002
- Kobe Foundation, Kirin to Commercialize Cord Blood Stem Cells
May 20, 2002
- Importance of Drug Patents Emphasized: Union Symposium
May 20, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
May 20, 2002
- Teijin to Form Teijin Pharma by Spinning Off Drug Division in 2003
May 20, 2002
- Terumo to Transfer Dialyzer Business to Asahi Medical
May 20, 2002
- BUSINESS NEWS IN BRIEF
May 20, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…